Promoted Content
Promoted Content

Find Clinical Drug Pipelines for Orthopedics/Orthopedic Surgery

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Study Phase filter
    Country filter
      News Type filter
        Company filter
          Product Type filter
            refresh

            Product Type Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ALLOB

            Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: ALLOB

            Highest Development Status: Phase II Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Catalent Pharma Solutions

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition November 16, 2020

            Details:

            Catalent has purchased the shares of SCTS and a purpose-built CGxP facility of approximately 41,000 square-foot. Catalent will undertake the manufacturing of clinical material for Bone Therapeutics’ drug, ALLOB, an allogeneic osteoblastic cell therapy product.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ALLOB

            Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: ALLOB

            Highest Development Status: Phase II Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Catalent Pharma Solutions

            Deal Size: $14.2 million Upfront Cash: Undisclosed

            Deal Type: Acquisition October 30, 2020

            Details:

            Agreements will streamline and economize the manufacturing operations of ALLOB, Bone Therapeutics’ allogeneic cell therapy product and will enable Bone Therapeutics to focus on the development of products from its differentiated MSC platform of cell and gene therapy.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ALLOB

            Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: ALLOB

            Highest Development Status: Phase II Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 14, 2020

            Details:

            The 24 month follow-up data of this Phase IIa clinical trial have shown that patients treated with ALLOB in spinal fusion procedure show a high incidence in fusion, and benefit from a sustained, clinically meaningful improvement in function and pain throughout the 24 months.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Bupivacaine,Meloxicam

            Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 04, 2020

            Details:

            HTX-011 reduced pain and opioid use after primary total knee arthroplasty, The study met all primary and key secondary endpoints, with HTX-011 demonstrating statistically significant reductions in pain intensity following surgery.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Calcium Phosphate,Blood-derived component

            Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 27, 2020

            Details:

            The Fast Track status offers the company benefits in improving and accelerating the company's trial on Bone Healing Accelerant in open tibia fractures to the target of a Biologic License Application.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Calcium Phosphate

            Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 07, 2020

            Details:

            Carmell to begin enrolling in pivotal clinical program for first-of-its-kind Plasma-based Bioactive Material product used in long-bone fractures as an adjunctive treatment.